A new trading day began on Friday, with Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) stock price up 2.07% from the previous day of trading, before settling in for the closing price of $8.22. BCRX’s price has ranged from $4.03 to $9.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 169.91% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 82.03%. With a float of $197.24 million, this company’s outstanding shares have now reached $208.54 million.
In an organization with 580 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.19%, operating margin of -0.54%, and the pretax margin is -19.29%.
Biocryst Pharmaceuticals Inc (BCRX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Biocryst Pharmaceuticals Inc is 5.61%, while institutional ownership is 78.48%. The most recent insider transaction that took place on Dec 13 ’24, was worth 52,780. In this transaction Director of this company sold 7,000 shares at a rate of $7.54, taking the stock ownership to the 86,638 shares. Before that another transaction happened on Dec 13 ’24, when Company’s Director proposed sale 7,000 for $7.51, making the entire transaction worth $52,584.
Biocryst Pharmaceuticals Inc (BCRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 82.03% per share during the next fiscal year.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Here are Biocryst Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.22 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Let’s dig in a bit further. During the last 5-days, its volume was 3.67 million. That was better than the volume of 3.3 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 94.94%. Additionally, its Average True Range was 0.41.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 68.19%, which indicates a significant decrease from 96.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.58% in the past 14 days, which was higher than the 49.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.85, while its 200-day Moving Average is $7.74. However, in the short run, Biocryst Pharmaceuticals Inc’s stock first resistance to watch stands at $8.52. Second resistance stands at $8.64. The third major resistance level sits at $8.82. If the price goes on to break the first support level at $8.22, it is likely to go to the next support level at $8.04. The third support level lies at $7.91 if the price breaches the second support level.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
With a market capitalization of 1.75 billion, the company has a total of 208,960K Shares Outstanding. Currently, annual sales are 450,710 K while annual income is -88,880 K. The company’s previous quarter sales were 131,530 K while its latest quarter income was -26,800 K.
